[go: up one dir, main page]

CL2019001711A1 - Composiciones y métodos para inhibir la acción de la arginasa. - Google Patents

Composiciones y métodos para inhibir la acción de la arginasa.

Info

Publication number
CL2019001711A1
CL2019001711A1 CL2019001711A CL2019001711A CL2019001711A1 CL 2019001711 A1 CL2019001711 A1 CL 2019001711A1 CL 2019001711 A CL2019001711 A CL 2019001711A CL 2019001711 A CL2019001711 A CL 2019001711A CL 2019001711 A1 CL2019001711 A1 CL 2019001711A1
Authority
CL
Chile
Prior art keywords
arginase
action
inhibiting
compositions
methods
Prior art date
Application number
CL2019001711A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Lijing Chen
Roland J Billedeau
Timothy F Stanton
Zandt Michael Van
Darren Whitehouse
Gunnar E Jagdmann Jr
Lene Raunkjaer Petersen
Francesco Parlati
Matthew I Gross
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001711(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CL2019001711A1 publication Critical patent/CL2019001711A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPUESTOS DERIVADOS DE OCTAHIDRO-[1,2]OXABOROCINO{6,7-c}PIRROL-1-{3H}ONA O SUS SALES, COMO INHBIDORES DE LA ACCIÓN DE LA ARGINASA; COMPOSICIÓN FARMACÉUTICA SÓLIDA QUE LOS COMPRENDE, ÚTIL PARA TRATAR O PREVENIR EL CÁNCER.
CL2019001711A 2016-12-22 2019-06-19 Composiciones y métodos para inhibir la acción de la arginasa. CL2019001711A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28

Publications (1)

Publication Number Publication Date
CL2019001711A1 true CL2019001711A1 (es) 2020-01-17

Family

ID=60972528

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001711A CL2019001711A1 (es) 2016-12-22 2019-06-19 Composiciones y métodos para inhibir la acción de la arginasa.

Country Status (33)

Country Link
US (4) US10287303B2 (es)
EP (2) EP3559009B1 (es)
JP (2) JP7018949B2 (es)
KR (1) KR102579849B1 (es)
CN (2) CN110382508B (es)
AU (2) AU2017382405B2 (es)
BR (1) BR112019012589B1 (es)
CA (1) CA3046987A1 (es)
CL (1) CL2019001711A1 (es)
CO (1) CO2019007839A2 (es)
CR (1) CR20190339A (es)
CY (1) CY1124483T1 (es)
DK (2) DK3559009T3 (es)
EC (1) ECSP19045511A (es)
ES (2) ES2970715T3 (es)
HR (1) HRP20210848T1 (es)
HU (1) HUE054272T2 (es)
IL (2) IL292677A (es)
LT (1) LT3559009T (es)
MD (1) MD3559009T2 (es)
MX (2) MX378460B (es)
MY (1) MY197478A (es)
NZ (1) NZ754364A (es)
PE (1) PE20191541A1 (es)
PH (1) PH12019501396A1 (es)
PL (1) PL3559009T3 (es)
PT (1) PT3559009T (es)
RS (1) RS61996B1 (es)
SG (2) SG10201911243WA (es)
SI (1) SI3559009T1 (es)
SM (1) SMT202100573T1 (es)
TW (1) TWI818902B (es)
WO (1) WO2018119440A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MY199220A (en) 2015-11-19 2023-10-20 Incyte Corp Heterocyclic compounds as immunomodulators
JP6911031B2 (ja) 2015-12-22 2021-07-28 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 免疫調節剤としての複素環化合物
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197280A (en) 2016-06-20 2023-06-09 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
PT3558990T (pt) * 2016-12-22 2022-11-21 Incyte Corp Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corporation derivados de benzo-oxazol como imunomoduladores
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2970715T3 (es) * 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
CN108322295B (zh) 2017-01-17 2021-12-24 维沃移动通信有限公司 一种边带信息的发送方法、接收方法、发送端和接收端
JOP20200197A1 (ar) 2018-02-17 2020-08-16 Astrazeneca Ab مثبطات أرجيناز وطرق لاستخدامها
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
AU2019323663B2 (en) * 2018-08-22 2022-07-14 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
PL3921033T3 (pl) * 2019-02-08 2024-01-15 Astrazeneca Ab Inhibitory arginazy i sposoby ich zastosowania
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
PH12022550754A1 (en) 2019-09-30 2023-08-23 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
RS66978B1 (sr) 2020-07-02 2025-07-31 Incyte Corp Triciklična jedinjenja uree kao inhibitori jak2 v617f
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
CN112387262B (zh) * 2020-11-10 2021-12-07 泰州学院 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
EP4460585A2 (en) * 2022-01-07 2024-11-13 The Trustees of Columbia University in the City of New York Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
US20240317744A1 (en) 2023-03-13 2024-09-26 Incyte Corporation Bicyclic Ureas As Kinase Inhibitors

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2000261978B2 (en) 2000-05-10 2006-07-06 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
AU2001275870A1 (en) 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080182882A1 (en) 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008061612A1 (en) 2006-11-21 2008-05-29 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
BRPI0719333A2 (pt) 2006-11-22 2014-02-04 Incyte Corp Midazotriazinas e imidazopirimidinas como inbidores de cinase
JP5386353B2 (ja) 2007-07-12 2014-01-15 山洋電気株式会社 二重反転式軸流送風機
EP2214660A2 (en) 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2011116299A2 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
RS57132B1 (sr) 2008-07-08 2018-07-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
EP2389352B1 (en) 2009-01-26 2019-05-08 The Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
EP2519508B1 (en) 2009-12-31 2014-07-02 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP5898177B2 (ja) 2010-04-22 2016-04-06 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
DK2563771T3 (en) 2010-04-24 2016-02-29 Viamet Pharmaceuticals Inc Metalloenzyminhibitorforbindelser
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
BR112013004517A2 (pt) 2010-08-27 2016-06-07 Merck Patent Gmbh derivados de triazolopirazina
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
WO2012058529A2 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103339115B (zh) 2010-11-13 2016-08-31 茵库恩制药有限公司 金属酶抑制剂化合物
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
NO2694640T3 (es) 2011-04-15 2018-03-17
EP3067350B1 (en) 2011-06-19 2018-06-13 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
JP6159318B2 (ja) 2011-06-19 2017-07-05 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
WO2012177728A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2751117A4 (en) 2011-08-30 2015-06-24 Innocrin Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
MX343534B (es) 2011-10-19 2016-11-09 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
US9957271B2 (en) * 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
SI2788343T1 (sl) 2011-12-11 2019-09-30 Viamet Pharmaceuticals (NC), Inc. Spojine inhibitorja metaloencimov
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN104066734B (zh) 2012-01-28 2017-03-29 默克专利股份公司 三唑并[4,5‑d]嘧啶衍生物
US9120804B2 (en) 2012-02-21 2015-09-01 Merck Patent Gmbh 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
AU2012370450B2 (en) 2012-02-21 2017-02-02 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
JP6049768B2 (ja) 2012-03-07 2016-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ トリアゾロピラジン誘導体
JP6152167B2 (ja) 2012-04-18 2017-06-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としての環拘束性類似体
EP2882746B1 (en) 2012-08-07 2016-12-07 Merck Patent GmbH Pyridopyrimidine derivatives as protein kinase inhibitors
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
EP2914263A4 (en) 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2903901A1 (en) 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
CN105026398B (zh) 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
MA38461B1 (fr) 2013-03-14 2021-10-29 Curadev Pharma Private Ltd Inhibiteurs de la voie de la kynurénine
KR20150129010A (ko) 2013-03-15 2015-11-18 브리스톨-마이어스 스큅 컴퍼니 Ido 억제제
TR201810399T4 (tr) 2013-03-15 2018-08-27 Gilead Sciences Llc İndolamin 2,3-dioksijenaz (ıdo) inhibitörleri.
EP2994471B1 (en) 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles as kinase inhibitors
US9447073B2 (en) 2013-05-28 2016-09-20 Viamet Pharmaceuticals, Inc. Fungicidal compositions
EA029126B1 (ru) 2013-07-01 2018-02-28 Бристол-Майерс Сквибб Компани Ингибиторы ido
US9895330B2 (en) 2013-07-11 2018-02-20 Bristol-Myers Squibb Company IDO inhibitors
WO2015017402A1 (en) 2013-07-29 2015-02-05 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of biofilm infections
CN105658643B (zh) 2013-08-27 2019-03-01 百时美施贵宝公司 Ido抑制剂
EP3060251A4 (en) 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
EA201991770A1 (ru) 2013-11-08 2019-12-30 Инсайт Холдингс Корпорейшн Способ синтеза ингибитора индоламин-2,3-диоксигеназы
KR20160108568A (ko) 2014-02-04 2016-09-19 인사이트 코포레이션 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
US9944664B2 (en) 2014-04-15 2018-04-17 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
US9663491B2 (en) 2014-04-15 2017-05-30 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
TW201619133A (zh) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
ES2751602T3 (es) 2014-09-05 2020-04-01 Merck Patent Gmbh Compuestos diaza y triaza tricíclicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cáncer
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
WO2016153078A1 (en) 2015-03-20 2016-09-29 Opiyo Sammy Oyoo Use of suramin and arginase inhibitors in malignant neoplasia
AR104176A1 (es) 2015-04-03 2017-07-05 Bristol Myers Squibb Co Inhibidores de ido (indolamina-2,3-dioxigenasa)
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
WO2016181348A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
MX385315B (es) 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
PT3368541T (pt) 2015-10-30 2020-07-06 Calithera Biosciences Inc Composições e métodos para inibição da atividade da arginase
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
ES2970715T3 (es) * 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
WO2018209290A1 (en) 2017-05-12 2018-11-15 Calithera Biosciences, Inc. Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
PL3559009T3 (pl) 2021-10-25
MX2019007471A (es) 2019-11-05
CA3046987A1 (en) 2018-06-28
PH12019501396A1 (en) 2019-12-02
IL292677A (en) 2022-07-01
CO2019007839A2 (es) 2019-10-21
AU2017382405A1 (en) 2019-06-27
JP2022066199A (ja) 2022-04-28
US20200339607A1 (en) 2020-10-29
SMT202100573T1 (it) 2021-11-12
IL267532A (en) 2019-08-29
EP3559009B1 (en) 2021-04-07
US12054501B2 (en) 2024-08-06
HRP20210848T1 (hr) 2021-07-09
PT3559009T (pt) 2021-05-04
SG10201911243WA (en) 2020-02-27
JP7018949B2 (ja) 2022-02-14
PE20191541A1 (es) 2019-10-23
MX378460B (es) 2025-03-10
ECSP19045511A (es) 2019-10-31
BR112019012589B1 (pt) 2022-11-29
TWI818902B (zh) 2023-10-21
ES2970715T3 (es) 2024-05-30
BR112019012589A2 (pt) 2019-11-19
KR102579849B1 (ko) 2023-09-18
DK3559009T3 (da) 2021-05-03
AU2017382405B2 (en) 2021-12-16
CN110382508A (zh) 2019-10-25
ES2881395T3 (es) 2021-11-29
WO2018119440A1 (en) 2018-06-28
SI3559009T1 (sl) 2021-08-31
NZ754364A (en) 2023-04-28
US20210261573A1 (en) 2021-08-26
MX2020013649A (es) 2021-02-26
IL267532B (en) 2022-06-01
DK3842442T3 (da) 2024-02-05
JP2020514271A (ja) 2020-05-21
HUE054272T2 (hu) 2021-09-28
AU2022201072A1 (en) 2022-03-10
CN110382508B (zh) 2022-08-02
US10287303B2 (en) 2019-05-14
EP3559009A1 (en) 2019-10-30
EP3842442B1 (en) 2023-11-01
US20190330244A1 (en) 2019-10-31
LT3559009T (lt) 2021-06-25
CN114989205A (zh) 2022-09-02
RS61996B1 (sr) 2021-07-30
US11021495B2 (en) 2021-06-01
SG10201911240PA (en) 2020-02-27
CY1124483T1 (el) 2022-07-22
MD3559009T2 (ro) 2021-07-31
CR20190339A (es) 2020-01-10
US10597411B2 (en) 2020-03-24
KR20190119579A (ko) 2019-10-22
MY197478A (en) 2023-06-19
US20180222926A1 (en) 2018-08-09
EP3842442A1 (en) 2021-06-30
TW201828948A (zh) 2018-08-16

Similar Documents

Publication Publication Date Title
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2017001126A1 (es) Agentes inmunoreguladores
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CL2017001124A1 (es) Agentes inmunomoduladores
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
DOP2018000058A (es) Inhibidores de ezh2
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
BR112016028255A2 (pt) agentes imunorreguladores
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
MX2017014128A (es) 2-tiopirimidinonas.
UY38472A (es) Moduladores de la expresión de foxp3
AR117079A1 (es) Moduladores de la expresión de foxp3
CL2017000872A1 (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)